Obesity and low target attainment rates in Chinese with type 2 diabetes

European Journal of Internal Medicine
Xing-Bo ChengMing-Chia Hsieh

Abstract

Although it is known that the prevalence of type 2 diabetes and obesity is increasing in China, there is little research into how obese or non-obese patients may differ in their attainment of treatment goals for type 2 diabetes. To do this, we assessed the attainment of American Diabetes Association (ADA)-recommended goals in Chinese with type 2 diabetes stratified by body mass index (BMI). This cross-sectional study enrolled 520 Chinese with type 2 diabetes to find out if they had attained the following ADA-recommended goals: HbA1c<7%, SBP<130 mm Hg, DBP<80 mm Hg, LDL-C<100mg/dl, TG<150 mg/dl, HDL-C>40 mg/dl for men and >50mg/dl for women. Only 44.4% of all participants achieved the blood pressure goal, 20.8% the HbA1c goal, 44.8% the LDL-C goal, 43.3% the HDL-C goal, and 66.8% the triglyceride goal. Obese patients were less likely than normal weight patients to achieve the blood pressure goal (OR, 0.474; 95% CI, 0.231-0.973; p = 0.01), the HDL goal (OR, 0.365; 95% CI, 0.163-0.817; p = 0.01), or the triglyceride goal (OR, 0.416; 95% CI, 0.212-0.817; p = 0.01), after adjusting for confounders. Compared to normal weight participants, the obese patients had a significantly higher prescription rates for statin, metformin and anti-...Continue Reading

References

Nov 12, 1992·The New England Journal of Medicine·H Yki-JärvinenP Seppälä
Mar 1, 1992·Journal of Internal Medicine·T SaneM R Taskinen
Oct 1, 1993·Annals of Internal Medicine·F X Pi-Sunyer
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jan 19, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C-H Tseng
Oct 2, 2007·The American Journal of Medicine·Seth UretskyCarl J Pepine
Dec 28, 2007·Diabetes Research and Clinical Practice·Swarna VarmaGretchen A Piatt
Jul 26, 2008·Postgraduate Medicine·Surya M ArthamHector O Ventura
Mar 26, 2010·The New England Journal of Medicine·Wenying YangUNKNOWN China National Diabetes and Metabolic Disorders Study Group
Oct 30, 2010·The American Journal of Cardiology·Vineet BhanUNKNOWN Guidelines Oriented Approach in Lipid Lowering (GOALL) Registry and Vascular Protection (VP) Registry Investigators
Feb 9, 2011·European Journal of Clinical Investigation·Ming-Chia HsiehShih-Te Tu
Sep 22, 2011·ClinicoEconomics and Outcomes Research : CEOR·Luca Degli EspostiEzio Degli Esposti

❮ Previous
Next ❯

Citations

Mar 13, 2021·BMC Medical Research Methodology·Jun Jie Benjamin SengLian Leng Low

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Related Papers

Diabetic Medicine : a Journal of the British Diabetic Association
S M Marshall, J H Barth
Diabetes Care
Simon R Heller, ADVANCE Collaborative Group
Lancet
Peter GaedeOluf Pedersen
© 2021 Meta ULC. All rights reserved